Search 

NeuroTronik Limited is a development-stage, venture-backed medical device company pursuing a unique neuromodulation approach to improve cardac output for patients who come to the hospital with Acute Heart Failure Syndrome. With a seasoned team of engineers, advisors, and investors, NeuroTronik is on-track in project milestone achievement. Though a moderately-sized project, the market potential is exceptional.

NeuroTronik is planning a $20 million Series B preferred stock financing in late 2015. Those proceeds are designed to take the therapy through and into commercial sales in Europe.

Our named investors are Hatteras Venture Partners, Synergy Life Science Partners, Mountain Group Capital, and Lord Baltimore Capital.

The CEO is Fred McCoy. The CTO is Steve Masson.

Norfolk Medical pioneered the oncology market in 1981 by developing one of the first vascular access ports for long-term access.  Since then, we have continued to develop innovative cutting-edge medical devices.  Our latest development is a device for diabetes that allows the body to be insulin independent.  Our device is the world's first active immunoisolation device that facilitates the exchange of oxygen, nutrients, and waste products while protecting against the bodies immune response without the use of additional drugs or immunosuppressant’s.  We are confident that the basic principles of the device can be applied to other applications from anemia and liver failure (NASH) to ALS.  We are currently in the pre-clinical stage of research and are actively looking for a strategic partner to develop this product. 

Novartis is a large pharmaceutical company formed in 1996 and based in Basel, Switzerland. Novartis is an active investor in emerging life science companies via in-licensing, strategic partnerships, and acquisitions. Novartis also has a corporate VC fund (Novartis Venture Fund). 

Novartis has seven divisions, all of which accept collaboration proposals athttps://partnering.novartis.com: 

Novartis Pharmaceuticals is the largest division of Novartis; the division seeks innovative therapeutics that have attained proof of concept in humans, drug delivery technologies, process scale-up/development technologies, and drug manufacturing technologies. Novartis Pharmaceuticals also seeks molecular diagnostics in the oncology field and companion diagnostics that are connected with drug treatments. In addition to in-licensing, Novartis Pharmaceuticals is interested in joint regional commercialization for therapeutic products that are on the market. 

Novartis Institutes for Biomedical Research focuses on early-stage compounds and research technologies (including software, assay tools, disease models, screening and imaging tools, as well as therapeutic discoveries at the pre-proof of concept stage). 

Novartis Vaccines & Diagnostics seeks vaccines in late-stage clinical trials or on the market, vaccine development candidates, and vaccine-related technologies such as delivery, formulation, and adjuvants. 

Novartis Consumer OTC seeks OTC products and prescription products that could be switched to OTC status. Additionally Novartis OTC is interested in scientifically proven nutraceuticals and dietary supplements, innovative packaging technology, drug delivery devices or enabling technology platforms. The fund also invests in medical devices. Indications that Novartis OTC invests in include respiratory diseases, digestive health, pain, analgesics, diseases of the skin, and behavioral disorders (smoking-cessation). 

Novartis Animal Health seeks opportunities in the veterinary, agbio and aquaculture sectors. Indications of interest include musculoskeletal diseases (arthritis), renal diseases, heart disease and allergies in pets, and infectious and parasitic diseases in livestock. Subsectors of interest include animal vaccines and bioprotection (insecticides, fly control). Additionally Novartis Animal Health is interested in drug delivery in animals. 

Sandoz focuses on generics and is also interested in anti-infectives and injectable oncology drugs. 

Alcon focuses on treatments for diseases of the eye, and is interested in therapeutic products, surgical products and over-the-counter ophthalmic products such as contact lenses and lens care products.

Novelogics Biotechnology Inc. has developed unique next generation antibody immunotherapies for treating multiple types of advanced cancers including colon and prostate cancers.  Immunotherapies for cancer are anticipated to be a $35B per year industry in the upcoming years.  

Cancer Drugs with Safety in Mind

From the beginning the novel and specific design of the therapeutic antibody drug minimizes the potential for autoimmune diseases or harming good cells with the bad.  We are dedicated to making cancer treatments that won't make you sick to get you better.

Unecumbered, Founder Owned

Novelogics has developed their assets in an unecumbered envriornment allowing investors to work directly with the team.  At this time the companyis 100% founder owned and undiluted.  Novelogics is anticipating an early exit and has begun discussions with pharmaceutical companies interested in this area.

In addition; a related Medical Device

In addition to the drug, Novelogics has a second PCT Patent pending for a related medical device with a readily available "go to" market in place. 

NSF Health Sciences offers clinical, regulatory, and quality consulting services across the total product lifecycle for innovative medical device, pharmaceutical, and biotechnology companies.  We specialize in helping companies balance FDA and worldwide regulatory requirements with their business needs.